Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Wirksamkeit und Sicherheit von Nemtabrutinib (MK-1026) bei Teilnehmern mit hämatologischen Malignomen (MK-1026-003)

23. Oktober 2026 aktualisiert von: Merck Sharp & Dohme LLC

Eine Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von MK-1026 bei Teilnehmern mit hämatologischen Malignomen

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

Studienübersicht

Detaillierte Beschreibung

This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).

Studientyp

Interventionell

Einschreibung (Geschätzt)

490

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Caba, Argentinien, C1114AAN
        • Rekrutierung
        • FUNDALEU ( Site 0104)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 5411 48771046
      • Córdoba, Argentinien, X5016KEH
        • Rekrutierung
        • Hospital Privado Universitario de Córdoba ( Site 0107)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +541569634187
      • Mendoza, Argentinien, M5500AYB
        • Abgeschlossen
        • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentinien, C1118AAT
        • Rekrutierung
        • Hospital Aleman ( Site 0102)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +541148277000
    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., Argentinien, C1431FWO
        • Rekrutierung
        • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +541152990247
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentinien, S2000DEJ
        • Rekrutierung
        • Fundacion Estudios Clinicos ( Site 0112)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +54 0341 238 4171
    • New South Wales
      • Sydney, New South Wales, Australien, 2747
        • Abgeschlossen
        • Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
    • Victoria
      • Box Hill, Victoria, Australien, 3128
        • Rekrutierung
        • Box Hill Hospital ( Site 0203)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +611300342255
    • Western Australia
      • Nedlands, Western Australia, Australien, 6009
        • Rekrutierung
        • Sir Charles Gairdner Hospital ( Site 0200)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +61864573333
      • Rio de Janeiro, Brasilien, 20231-050
        • Rekrutierung
        • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +552132076564
      • São Paulo, Brasilien, 01321-001
        • Rekrutierung
        • Hospital Paulistano - Amil Clinical Research ( Site 0311)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +551130161340
      • São Paulo, Brasilien, 01321-001
        • Aktiv, nicht rekrutierend
        • BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
    • São Paulo
      • São Paulo, São Paulo, Brasilien, 05403-000
        • Rekrutierung
        • Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 551145737543
    • Anhui
      • Hefei, Anhui, China, 230071
        • Aktiv, nicht rekrutierend
        • Anhui Provincial Hospital ( Site 2808)
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100191
        • Rekrutierung
        • Peking University Third Hospital-Hematology ( Site 2827)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 010-82266699
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400072
        • Aktiv, nicht rekrutierend
        • The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
    • Guangdong
      • Guangzhou, Guangdong, China, 510060
        • Aktiv, nicht rekrutierend
        • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
    • Guangxi
      • Liuzhou, Guangxi, China, 545006
        • Rekrutierung
        • Liuzhou People's Hospital ( Site 2817)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8607722662950
      • Nanning, Guangxi, China, 530028
        • Rekrutierung
        • Guangxi Medical University Cancer Hospital ( Site 2814)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8607715323174
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Rekrutierung
        • Henan Cancer Hospital-hematology department ( Site 2802)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 0371-65588007
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Rekrutierung
        • Wuhan Union Hospital ( Site 2816)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8618627091655
    • Hunan
      • Changsha, Hunan, China, 410011
        • Rekrutierung
        • The Second Xiangya Hospital of Central South University ( Site 2820)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8613975806137
      • Changsha, Hunan, China, 410013
        • Rekrutierung
        • Hunan Cancer Hospital ( Site 2822)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 0731-88651669
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Rekrutierung
        • Jiangsu Province Hospital ( Site 2823)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 025-86211033
      • Xuzhou, Jiangsu, China, 221000
        • Abgeschlossen
        • The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Rekrutierung
        • The First Affiliated Hospital of Nanchang University ( Site 2815)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 13970038386
    • Jilin
      • Changchun, Jilin, China, 130021
        • Rekrutierung
        • The First Hospital of Jilin University-Hematology ( Site 2803)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 0431-88786014
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Rekrutierung
        • Fudan University Shanghai Cancer Center ( Site 2801)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8602164175590
      • Shanghai, Shanghai Municipality, China, 200040
        • Rekrutierung
        • Huashan Hospital, Fudan University ( Site 2821)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 021-52889999
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Rekrutierung
        • West China Hospital Sichuan University ( Site 2810)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +86028-85422114
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 301617
        • Rekrutierung
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8615900265415
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310002
        • Rekrutierung
        • The First Affiliated Hospital, Zhejiang University ( Site 2826)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 057187236114
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Deutschland, 89081
        • Rekrutierung
        • Universitaetsklinikum Ulm. ( Site 0906)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: + 49 731 500 45901
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Deutschland, 50937
        • Rekrutierung
        • Universitaetsklinikum Koeln ( Site 0901)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +4922147897046
      • Siegen, North Rhine-Westphalia, Deutschland, 57072
        • Abgeschlossen
        • St. Marien-Krankenhaus Siegen ( Site 0914)
    • Saxony
      • Dresden, Saxony, Deutschland, 01307
        • Rekrutierung
        • Universitaetsklinikum Carl Gustav Carus ( Site 0902)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 0049 351 458 5692
    • Central Jutland
      • Aarhus N, Central Jutland, Dänemark, 8200
        • Abgeschlossen
        • Aarhus University Hospital ( Site 0702)
    • North Denmark
      • Aalborg, North Denmark, Dänemark, 9000
        • Rekrutierung
        • Aalborg Universitetshospital ( Site 0703)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +45 97660000
    • Region Sjælland
      • Koege, Region Sjælland, Dänemark, 4600
        • Rekrutierung
        • Sjællands Universitetshospital Køge ( Site 0701)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +45 46323200
    • Region Syddanmark
      • Odense C, Region Syddanmark, Dänemark, 5000
        • Abgeschlossen
        • Odense University Hospital ( Site 0705)
      • Paris, Frankreich, 75010
        • Rekrutierung
        • Hopital Saint Louis ( Site 0805)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +33142499236
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, Frankreich, 06202
        • Rekrutierung
        • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +33 4 92 03 57 85
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite, Auvergne-Rhône-Alpes, Frankreich, 69495
        • Rekrutierung
        • Centre Hospitalier Lyon-Sud ( Site 0804)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +33478864348
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, Frankreich, 13009
        • Rekrutierung
        • Institut Paoli-Calmettes ( Site 0803)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +33491223537
    • Yvelines
      • Le Chesnay, Yvelines, Frankreich, 78150
        • Abgeschlossen
        • Centre Hospitalier de Versailles ( Site 0809)
      • Dublin, Irland, Dublin 9
        • Rekrutierung
        • Beaumont Hospital ( Site 2900)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +35318092010
      • Limerick, Irland, V94 F858
        • Aktiv, nicht rekrutierend
        • University Hospital Limerick ( Site 2903)
      • Afula, Israel, 1834111
        • Rekrutierung
        • Ha Emek Medical Center ( Site 1305)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 972-46494052
      • Beersheba, Israel, 8410101
        • Rekrutierung
        • Soroka Medical Center ( Site 1307)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +97286403827
      • Haifa, Israel, 3109601
        • Rekrutierung
        • Rambam Medical Center ( Site 1301)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +97247772547
      • Jerusalem, Israel, 9112001
        • Rekrutierung
        • Hadassah Ein Karem Jerusalem ( Site 1300)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +97226778180
      • Ramat Gan, Israel, 5262001
        • Rekrutierung
        • Chaim Sheba Medical Center ( Site 1302)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +97235308401
      • Rehovot, Israel, 76100
        • Rekrutierung
        • Kaplan Medical Center ( Site 1304)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +97289441726
      • Tel Aviv, Israel, 6423906
        • Rekrutierung
        • Sourasky Medical Center ( Site 1303)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +97236973782
      • Bari, Italien, 70124
        • Abgeschlossen
        • Istituto Tumori Giovanni Paolo II ( Site 1409)
      • Bologna, Italien, 40138
        • Rekrutierung
        • A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +390516363680
      • Brescia, Italien, 25123
        • Rekrutierung
        • ASST Spedali Civili di Brescia ( Site 1408)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +39 0303996416
      • Milan, Italien, 20132
        • Rekrutierung
        • IRCCS Ospedale San Raffaele ( Site 1402)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 00390226434797
      • Naples, Italien, 80131
        • Rekrutierung
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +39 0815903 382
      • Pavia, Italien, 27100
        • Rekrutierung
        • Fondazione IRCCS Policlinico San Matteo ( Site 1407)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +39 0382503084
      • Reggio Emilia, Italien, 42123
        • Rekrutierung
        • IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +39 0522295654
      • Roma, Italien, 00161
        • Abgeschlossen
        • Policlinico Umberto I ( Site 1404)
    • Alberta
      • Calgary, Alberta, Kanada, T2N 5G2
        • Rekrutierung
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 4035213723
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Rekrutierung
        • The Ottawa Hospital ( Site 0404)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 613 737-7700
      • Toronto, Ontario, Kanada, M5G 2M9
        • Rekrutierung
        • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 416-946-2827
    • Quebec
      • Montreal, Quebec, Kanada, H3T 1E2
        • Rekrutierung
        • Jewish General Hospital ( Site 0400)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 5143408222 x 24572
      • Montreal, Quebec, Kanada, H1T 2M4
        • Rekrutierung
        • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 5142523400
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 30-727
        • Rekrutierung
        • Pratia MCM Krakow ( Site 1601)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 48 12 2954135
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polen, 50-367
        • Abgeschlossen
        • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 02-781
        • Rekrutierung
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +48225462223
    • Opole Voivodeship
      • Opole, Opole Voivodeship, Polen, 45-061
        • Abgeschlossen
        • Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
    • Pomeranian Voivodeship
      • Gdynia, Pomeranian Voivodeship, Polen, 81-519
        • Abgeschlossen
        • Szpitale Pomorskie Sp. z o.o. ( Site 1600)
      • Brasov, Rumänien, 500052
        • Rekrutierung
        • Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 0729075567
      • Iași, Rumänien, 700483
        • Rekrutierung
        • Institutul Regional de Oncologie Iasi ( Site 1801)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 40374278811
    • Bucharest
      • Bucharest, Bucharest, Rumänien, 030171
        • Rekrutierung
        • Spitalul Clinic Colțea ( Site 1805)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 0040213874100
    • Constanța County
      • Ovidiu, Constanța County, Rumänien, 905900
        • Abgeschlossen
        • Ovidius Clinical Hospital ( Site 1804)
    • Canton Ticino
      • Bellinzona, Canton Ticino, Schweiz, 6500
        • Rekrutierung
        • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +41918118540
    • Canton of Bern
      • Bern, Canton of Bern, Schweiz, 3010
        • Rekrutierung
        • Inselspital Bern ( Site 2303)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +41316329023
      • Alicante, Spanien, 03010
        • Rekrutierung
        • Hospital General Universitario de Alicante ( Site 2007)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 965 93 30 00
      • Barcelona, Spanien, 08035
        • Rekrutierung
        • Hospital Universitari Vall d'Hebron ( Site 2001)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +34934893806
      • Madrid, Spanien, 28041
        • Rekrutierung
        • Hospital Universitario 12 de Octubre ( Site 2003)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +34917792809
      • Madrid, Spanien, 28222
        • Rekrutierung
        • Hospital Puerta de Hierro ( Site 2009)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +34911916000
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spanien, 08908
        • Rekrutierung
        • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +34932607750
    • Castille and León
      • Salamanca, Castille and León, Spanien, 37007
        • Rekrutierung
        • Hospital Universitario de Salamanca ( Site 2002)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 34923 29 11 00x55974
    • La Coruna
      • A Coruña, La Coruna, Spanien, 15006
        • Rekrutierung
        • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 34981178000
      • Seoul, Südkorea, 03722
        • Rekrutierung
        • Severance Hospital Yonsei University Health System ( Site 2201)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +82222281972
      • Seoul, Südkorea, 06351
        • Rekrutierung
        • Samsung Medical Center ( Site 2200)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +82234106548
      • Hradec Králové, Tschechien, 500 05
        • Rekrutierung
        • Fakultni nemocnice Hradec Kralove ( Site 0601)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +420495832159
    • Brno-mesto
      • Brno, Brno-mesto, Tschechien, 625 00
        • Rekrutierung
        • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +420532233642
      • Ankara, Türkei (türkiye), 06590
        • Rekrutierung
        • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +903125957099
      • Istanbul, Türkei (türkiye), 34365
        • Abgeschlossen
        • VKV Amerikan Hastanesi ( Site 2403)
      • Istanbul, Türkei (türkiye), 34381
        • Rekrutierung
        • Sisli Florence Nightingale Hastanesi ( Site 2407)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +90 542 502 50 75
      • Izmir, Türkei (türkiye), 35340
        • Aktiv, nicht rekrutierend
        • Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
    • Istanbul
      • Stanbul, Istanbul, Türkei (türkiye), 34214
        • Aktiv, nicht rekrutierend
        • Mega Medipol-Hematology ( Site 2406)
      • Kyiv, Ukraine, 03022
        • Rekrutierung
        • National Cancer Institute ( Site 2507)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +380672091427
    • Cherkasy Oblast
      • Cherkassy, Cherkasy Oblast, Ukraine, 18009
        • Aktiv, nicht rekrutierend
        • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine, 76008
        • Abgeschlossen
        • Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukraine, 79044
        • Rekrutierung
        • Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +380322352276
      • Budapest, Ungarn, 1122
        • Rekrutierung
        • Orszagos Onkologiai Intezet ( Site 1200)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +3612248600
    • Baranya
      • Pécs, Baranya, Ungarn, 7624
        • Rekrutierung
        • Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +3672536000
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Ungarn, 4032
        • Rekrutierung
        • Debreceni Egyetem Klinikai Kozpont ( Site 1201)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +3652255196
    • Szabolcs-Szatmár-Bereg
      • Nyíregyháza, Szabolcs-Szatmár-Bereg, Ungarn, 4400
        • Rekrutierung
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +3642599700
    • Arkansas
      • Springdale, Arkansas, Vereinigte Staaten, 72762
        • Rekrutierung
        • Highlands Oncology Group ( Site 2728)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 479-872-8130
    • California
      • La Jolla, California, Vereinigte Staaten, 92093-0698
        • Rekrutierung
        • University of California San Diego Moores Cancer Center ( Site 2717)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 858-534-5201
      • Torrance, California, Vereinigte Staaten, 90502
        • Abgeschlossen
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
    • Colorado
      • Denver, Colorado, Vereinigte Staaten, 80218
        • Rekrutierung
        • Colorado Blood Cancer Institute ( Site 2726)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 720-754-4800
    • Kentucky
      • Louisville, Kentucky, Vereinigte Staaten, 40202
        • Abgeschlossen
        • The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Aktiv, nicht rekrutierend
        • Mayo Clinic - Rochester ( Site 2706)
    • New Jersey
      • East Brunswick, New Jersey, Vereinigte Staaten, 08816
        • Rekrutierung
        • Astera Cancer Care ( Site 2732)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 732-672-6405
      • Hackensack, New Jersey, Vereinigte Staaten, 07601
        • Rekrutierung
        • John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 551-996-3003
    • North Dakota
      • Fargo, North Dakota, Vereinigte Staaten, 58102
        • Abgeschlossen
        • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
    • Texas
      • Dallas, Texas, Vereinigte Staaten, 75390
        • Rekrutierung
        • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 972-695-9450
    • Washington
      • Spokane, Washington, Vereinigte Staaten, 99208
        • Rekrutierung
        • Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 509-462-2273
      • Manchester, Vereinigtes Königreich, M20 4BX
        • Rekrutierung
        • The Christie NHS Foundation Trust ( Site 2602)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 01619561217
    • Bristol, City of
      • Bristol, Bristol, City of, Vereinigtes Königreich, BS2 8ED
        • Rekrutierung
        • Bristol Haematology and Oncology Centre ( Site 2610)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 01173426733
    • England
      • Nottingham, England, Vereinigtes Königreich, NG5 1PF
        • Rekrutierung
        • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +441159691169
      • Windsor, England, Vereinigtes Königreich, SL4 3HD
        • Rekrutierung
        • GenesisCare - Windsor ( Site 2608)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +447989474250
    • London, City of
      • London, London, City of, Vereinigtes Königreich, W1G 6AD
        • Rekrutierung
        • Sarah Cannon Research Institute UK ( Site 2612)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 02032195234
    • Oxfordshire
      • Oxford, Oxfordshire, Vereinigtes Königreich, OX4 6LB
        • Rekrutierung
        • GenesisCare - Oxford ( Site 2607)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +447989474250
    • Suffolk
      • Newmarket, Suffolk, Vereinigtes Königreich, CB8 7XN
        • Rekrutierung
        • GenesisCare - Cambridge ( Site 2611)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 01223 655145
    • Surrey
      • Sutton, Surrey, Vereinigtes Königreich, SM2 5PT
        • Rekrutierung
        • The Royal Marsden NHS Foundation Trust. ( Site 2606)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 020 8642 6011

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
  • Has a life expectancy of at least 3 months, based on the investigator assessment
  • Has the ability to swallow and retain oral medication
  • Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Has adequate organ function
  • Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
  • Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
  • Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART

Part 1 and Part 2 (Cohorts A to C and J)

  • Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with

    • At least 2 lines of prior therapy (Part 1 only)
    • Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines
    • Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive
    • Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy
    • Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J
    • Has active disease for CLL/SLL clearly documented to initiate therapy
    • For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)

Part 2 (Cohorts D to G)

- Has a confirmed diagnosis of and meets the following prior therapy requirements:

  • Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)
  • Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)
  • Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen
  • Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)
  • Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan
  • Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening

Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi

  • Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease
  • Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%
  • Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival

Exclusion Criteria:

  • Has active HBV/HCV infection (Part 1 and Part 2)
  • Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
  • Has active central nervous system (CNS) disease
  • Has an active infection requiring systemic therapy
  • Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • Has any clinically significant gastrointestinal abnormalities that might alter absorption
  • History of severe bleeding disorders

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Nemtabrutinib

Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.

Nemtabrutinib tablets administered orally QD.

Andere Namen:
  • MK-1026
  • ARQ531

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
Zeitfenster: Up to ~56 days (Cycles 1-2, cycle = 28 days)

DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting >7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for >1 week (with exceptions); missing >25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity.

Up to ~56 days (Cycles 1-2, cycle = 28 days)
Part 1: Number of participants experiencing adverse events (AEs)
Zeitfenster: Up to ~71 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.

Up to ~71 months
Part 1: Number of participants discontinuing study treatment due to AEs
Zeitfenster: Up to ~42 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1.

Up to ~42 months
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
Zeitfenster: Up to ~61 months

ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~61 months
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
Zeitfenster: Up to ~61 months

ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography [CT]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters [SPD] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.

Up to ~61 months
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
Zeitfenster: Up to ~71 months

ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal).

Up to ~71 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 1: Area Under the Curve (AUC) of Nemtabrutinib
Zeitfenster: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
Zeitfenster: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
Zeitfenster: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
Zeitfenster: Up to ~71 months

ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~71 months
Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
Zeitfenster: Up to ~71 months

For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~71 months
Part 2: Number of participants experiencing AEs
Zeitfenster: Up to ~61 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.

Up to ~61 months
Part 2: Number of participants discontinuing study treatment due to AEs
Zeitfenster: Up to ~42 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2.

Up to ~42 months
Part 2: AUC of Nemtabrutinib
Zeitfenster: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: Cmin of Nemtabrutinib
Zeitfenster: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: Cmax of Nemtabrutinib
Zeitfenster: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
Zeitfenster: Up to ~61 months

For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~61 months
Part 2: DOR per Lugano criteria 2014 as assessed by ICR
Zeitfenster: Up to ~61 months

For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.

Up to ~61 months
Part 2: DOR per IWWM criteria 2014 as assessed by ICR
Zeitfenster: Up to ~61 months

For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal).

Up to ~61 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Medical Director, Merck Sharp & Dohme LLC

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

5. April 2021

Primärer Abschluss (Geschätzt)

4. Januar 2029

Studienabschluss (Geschätzt)

4. Januar 2029

Studienanmeldedaten

Zuerst eingereicht

25. Januar 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. Januar 2021

Zuerst gepostet (Tatsächlich)

28. Januar 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

27. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

23. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren